The review concluded that there was a small increased risk of overall infections with short-term use of tumour necrosis factor antagonists for psoriasis and no difference in serious infections or malignancies. The review was generally well conducted and the authors' conclusions seem reliable. The authors noted that results were limited by the rarity of events and short follow-up.
Authors' objectives
To examine the risks of infection and malignancy with use of tumour necrosis factor (TNF) antagonists in patients with psoriatic disease. 
Searching

Study selection
Randomised controlled trials (RCTs) of etanercept, adalimumab, infliximab, golimumab and certolizumab (as monotherapy) were eligible for inclusion if they compared these with placebo for the treatment of adult patients with moderate to severe plaque psoriasis and/or psoriatic arthritis. Trials had to have a follow-up of at least 12 weeks.
The included trials studied 25mg to 50mg etanercept, 40mg to 80mg adalimumab, 3mg to 5mg/kg infliximab, 50mg to 100mg golimumab and 200mg to 400mg certolizumab in patients with moderate to severe plaque psoriasis or psoriatic arthritis. All psoriatic arthritis trials allowed patients to use disease modifying anti-rheumatic drugs (DMARDs).
The authors did not state how many reviewers performed study selection.
Assessment of study quality
Validity assessment was undertaken using the Jadad criteria of randomisation, blinding and withdrawals and drop-outs to give a maximum score out of five. Trials that scored less than 3 on the Jadad scale were excluded.
Two reviewers independently performed validity assessment.
Data extraction
Data were extracted on infections and malignancies on an intention-to-treat basis and were used to calculate odds ratios and their 95% confidence intervals.
Two reviewers independently performed data extraction.
Methods of synthesis
A Mantel-Haenszel fixed-effect meta-analysis was used to calculate pooled odds ratios and their 95% confidence intervals. Incidence rate ratios were calculated. The number needed to harm (NNH) was estimated. Statistical heterogeneity was assessed using Ι². Publication bias was assessed using funnel plots and Egger's test.
Subgroup analyses were performed by indication and drug. Sensitivity analysis used the random-effects model, excluded individual trials and used different continuity corrections.
